Around 250,000 people in Austria suffer from psoriasis (Ps). A third of them go on to develop inflammation of the joints (psoriatic arthritis, PsA) as a result of this chronic skin condition. Triggers for the condition, which usually occurs in adulthood, include stress and UV radiation. However, a predisposition to psoriasis can also be inherited.
The S100A9 gene has long been the focus of many international studies. The activation of this gene in skin and immune cells is a risk factor for the development of Ps and PsA. Researchers at MedUni Vienna have now discovered that the severity of the condition can be positively influenced if the gene is inhibited systemically throughout the body rather than locally on the skin. The research group led by Erwin Wagner, from the University Clinic for Dermatology and the Clinical Institute for Laboratory Medicine at MedUni Vienna, is thus laying the foundations for a paradigm shift in the treatment, diagnosis and prevention of psoriasis and psoriatic arthritis.
Previous basic research by Wagner’s team has shown that the symptoms of psoriasis disappear when the S100A9 gene is inactivated in all cells of the body. The current preclinical experiments have revealed the specific influence that skin and immune cells – in which S100A9 is produced – have on the severity of the disease.
“We now know that the inflammatory responses in psoriasis and psoriatic arthritis are exacerbated when S100A9 is inhibited only in skin cells,” says Wagner, summarising the key finding of the study. Consequently, drugs that inhibit S100A9 must be administered systemically in the form of tablets or infusions.
Reference:
Medical University of Vienna
Mellor LF et al., Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease, Annals of the Rheumatic Diseases, online first
doi: https://dx.doi.org/10.1136/annrheumdis-2022-222229